SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Portola Pharmaceuticals, Inc. Announces Upcoming Oral Presentation of Data on PRT4445, a First-in-Class Universal Factor Xa Inhibitor Antidote, at European Society of Cardiology 2012 Congress